{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:20:16Z","timestamp":1791937216908,"version":"4.3.4"},"reference-count":155,"publisher":"The Endocrine Society","issue":"11","license":[{"start":{"date-parts":[[2025,8,16]],"date-time":"2025-08-16T00:00:00Z","timestamp":1755302400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100004731","name":"Zhejiang Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["No. LTGY24H070003"],"award-info":[{"award-number":["No. LTGY24H070003"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017531","name":"Medical and Health Research Project of Zhejiang Province","doi-asserted-by":"publisher","award":["No. 2024KY1199"],"award-info":[{"award-number":["No. 2024KY1199"]}],"id":[{"id":"10.13039\/501100017531","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Zhejiang Province Science and Technology","award":["No. 2024C03269"],"award-info":[{"award-number":["No. 2024C03269"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The rising global incidence of type 2 diabetes mellitus and obesity underscores a critical public health challenge, with obesity serving as a primary contributor to insulin resistance. Current treatment modalities, including SGLT2 inhibitors and GLP-1 receptor agonists, have shown efficacy in glycemic control and weight management but remain insufficient for all patients. This review focuses on novel dual and triple agonists targeting glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), glucagon, and growth differentiation factor 15 (GDF15) due to their emerging clinical importance and recent preclinical progress. Other peptide-based therapies, such as amylin analogs, are beyond the scope of this work and will be addressed in future reviews. Evidence suggests that these novel agents not only improve metabolic parameters but may also offer cardioprotective and anti-inflammatory benefits. While advancements in understanding their mechanisms of action are promising, the safety profiles of these treatments warrant careful evaluation due to potential adverse effects. This review aims to provide a comprehensive overview of the evolving landscape of antidiabetic pharmacotherapy, emphasizing the unique benefits and challenges of emerging agents to optimize clinical outcomes in type 2 diabetes mellitus management.<\/jats:p>","DOI":"10.1210\/endocr\/bqaf130","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T11:59:57Z","timestamp":1755172797000},"source":"Crossref","is-referenced-by-count":11,"title":["Novel Dual and Triple Agonists Targeting GLP-1, GIP, Glucagon, and GDF15 for Type 2 Diabetes and Obesity Management"],"prefix":"10.1210","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-4430-9311","authenticated-orcid":false,"given":"Jiudan","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University , Hangzhou 310009 ,","place":["China"]},{"name":"Department of Endocrinology, Diabetes and Nutrition, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin , Berlin 12203 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shriya","family":"Sanan","sequence":"additional","affiliation":[{"name":"Hindu Rao Hospital , New Delhi 110007 ,","place":["India"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Csanalosi","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin , Berlin 12203 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2779-0255","authenticated-orcid":false,"given":"Chao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, The Second Affiliated Hospital, School of Medicine, Zhejiang University , Hangzhou 310009 ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas F H","family":"Pfeiffer","sequence":"additional","affiliation":[{"name":"Department of Endocrinology, Diabetes and Nutrition, Charit\u00e9-Universit\u00e4tsmedizin Berlin, Corporate Member of Freie Universit\u00e4t Berlin, Humboldt-Universit\u00e4t zu Berlin , Berlin 12203 ,","place":["Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,8,16]]},"reference":[{"issue":"6","key":"2025100907021029600_bqaf130-B1","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tem.2020.02.006","article-title":"How may GIP enhance the therapeutic efficacy of GLP-1?","volume":"31","author":"Samms","year":"2020","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"2025100907021029600_bqaf130-B2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.cmet.2017.07.011","article-title":"The sustained effects of a dual GIP\/GLP-1 receptor agonist, NNC0090-2746, in patients with type 2 diabetes","volume":"26","author":"Frias","year":"2017","journal-title":"Cell Metab"},{"issue":"12","key":"2025100907021029600_bqaf130-B3","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrendo.2010.187","article-title":"The metabolic actions of glucagon revisited","volume":"6","author":"Habegger","year":"2010","journal-title":"Nat Rev Endocrinol"},{"key":"2025100907021029600_bqaf130-B4","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.peptides.2016.12.012","article-title":"Glucagon increases insulin levels by stimulating insulin secretion without effect on insulin clearance in mice","volume":"88","author":"Song","year":"2017","journal-title":"Peptides"},{"issue":"1","key":"2025100907021029600_bqaf130-B5","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1038\/s41598-017-01258-6","article-title":"Phosphorylation of the mitochondrial autophagy receptor Nix enhances its interaction with LC3 proteins","volume":"7","author":"Rogov","year":"2017","journal-title":"Sci Rep"},{"issue":"1","key":"2025100907021029600_bqaf130-B6","doi-asserted-by":"crossref","first-page":"10342","DOI":"10.1038\/s41467-024-54080-w","article-title":"The dual GLP-1\/glucagon receptor agonist G49 mimics bariatric surgery effects by inducing metabolic rewiring and inter-organ crosstalk","volume":"15","author":"Valdecantos","year":"2024","journal-title":"Nat Commun"},{"issue":"7798","key":"2025100907021029600_bqaf130-B7","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/s41586-020-2074-6","article-title":"Glucagon stimulates gluconeogenesis by INSP3R1-mediated hepatic lipolysis","volume":"579","author":"Perry","year":"2020","journal-title":"Nature"},{"issue":"5","key":"2025100907021029600_bqaf130-B8","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molmed.2016.03.005","article-title":"Reappraisal of GIP pharmacology for metabolic diseases","volume":"22","author":"Finan","year":"2016","journal-title":"Trends Mol Med"},{"issue":"2","key":"2025100907021029600_bqaf130-B9","doi-asserted-by":"crossref","first-page":"235","DOI":"10.2337\/db16-0994","article-title":"Glucagon and amino acids are linked in a mutual feedback cycle: the liver-alpha-cell axis","volume":"66","author":"Holst","year":"2017","journal-title":"Diabetes"},{"issue":"s1","key":"2025100907021029600_bqaf130-B10","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1463-1326.2011.01454.x","article-title":"Physiologic action of glucagon on liver glucose metabolism","volume":"13","author":"Ramnanan","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2025100907021029600_bqaf130-B11","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/gast.1999.0029900433","article-title":"Signal transduction and hepatocellular bile acid transport: cross talk between bile acids and second messengers","volume":"117","author":"Bouscarel","year":"1999","journal-title":"Gastroenterology"},{"issue":"6","key":"2025100907021029600_bqaf130-B12","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/j.cmet.2013.04.008","article-title":"Pharmacology, physiology, and mechanisms of incretin hormone action","volume":"17","author":"Campbell","year":"2013","journal-title":"Cell Metab"},{"issue":"1","key":"2025100907021029600_bqaf130-B13","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1210\/er.2006-0007","article-title":"Alpha-cells of the endocrine pancreas: 35 years of research but the enigma remains","volume":"28","author":"Gromada","year":"2007","journal-title":"Endocr Rev"},{"issue":"4","key":"2025100907021029600_bqaf130-B14","doi-asserted-by":"crossref","first-page":"E751","DOI":"10.1152\/ajpendo.90295.2008","article-title":"Insulin as a physiological modulator of glucagon secretion","volume":"295","author":"Bansal","year":"2008","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"6","key":"2025100907021029600_bqaf130-B15","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"issue":"5910","key":"2025100907021029600_bqaf130-B16","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/302716a0","article-title":"Hamster preproglucagon contains the sequence of glucagon and two related peptides","volume":"302","author":"Bell","year":"1983","journal-title":"Nature"},{"issue":"1","key":"2025100907021029600_bqaf130-B17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2337\/db18-0317","article-title":"GLP-1 receptor in pancreatic alpha-cells regulates glucagon secretion in a glucose-dependent bidirectional manner","volume":"68","author":"Zhang","year":"2019","journal-title":"Diabetes"},{"issue":"3","key":"2025100907021029600_bqaf130-B18","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-201X.1996.42256000.x","article-title":"Distribution of GLP-1 and PACAP receptors in human tissues","volume":"157","author":"Wei","year":"1996","journal-title":"Acta Physiol Scand"},{"issue":"4","key":"2025100907021029600_bqaf130-B19","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/j.1471-4159.2004.02914.x","article-title":"The expression of GLP-1 receptor mRNA and protein allows the effect of GLP-1 on glucose metabolism in the human hypothalamus and brainstem","volume":"92","author":"Alvarez","year":"2005","journal-title":"J Neurochem"},{"issue":"4","key":"2025100907021029600_bqaf130-B20","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1210\/en.2013-1934","article-title":"GLP-1 receptor localization in monkey and human tissue: novel distribution revealed with extensively validated monoclonal antibody","volume":"155","author":"Pyke","year":"2014","journal-title":"Endocrinology"},{"key":"2025100907021029600_bqaf130-B21","doi-asserted-by":"crossref","first-page":"101014","DOI":"10.1016\/j.molmet.2020.101014","article-title":"Human islets contain a subpopulation of glucagon-like peptide-1 secreting alpha cells that is increased in type 2 diabetes","volume":"39","author":"Campbell","year":"2020","journal-title":"Mol Metab"},{"issue":"10","key":"2025100907021029600_bqaf130-B22","doi-asserted-by":"crossref","first-page":"2064","DOI":"10.1007\/s00125-020-05196-3","article-title":"Alpha cell regulation of beta cell function","volume":"63","author":"Moede","year":"2020","journal-title":"Diabetologia"},{"issue":"1","key":"2025100907021029600_bqaf130-B23","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.metabol.2013.09.010","article-title":"Anti-diabetic actions of glucagon-like peptide-1 on pancreatic beta-cells","volume":"63","author":"Lee","year":"2014","journal-title":"Metabolism"},{"issue":"9","key":"2025100907021029600_bqaf130-B24","first-page":"B4181","article-title":"Role of GLP-1 induced glucagon suppression in type 2 diabetes mellitus","volume":"57","author":"Hare","year":"2010","journal-title":"Dan Med Bull"},{"issue":"2","key":"2025100907021029600_bqaf130-B25","doi-asserted-by":"crossref","first-page":"E318","DOI":"10.1152\/ajpendo.00191.2010","article-title":"GLP-1 treatment reduces endogenous insulin resistance via activation of central GLP-1 receptors in mice fed a high-fat diet","volume":"299","author":"Parlevliet","year":"2010","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"9","key":"2025100907021029600_bqaf130-B26","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.molmet.2014.09.005","article-title":"GLP-1 receptor agonism ameliorates hepatic VLDL overproduction and de novo lipogenesis in insulin resistance","volume":"3","author":"Taher","year":"2014","journal-title":"Mol Metab"},{"issue":"8","key":"2025100907021029600_bqaf130-B27","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/dom.13761","article-title":"Effect of liraglutide on estimates of lipolysis and lipid oxidation in obese patients with stable coronary artery disease and newly diagnosed type 2 diabetes: a randomized trial","volume":"21","author":"Anholm","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"4","key":"2025100907021029600_bqaf130-B28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"issue":"2","key":"2025100907021029600_bqaf130-B29","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s40519-016-0352-y","article-title":"GLP-1 receptor independent pathways: emerging beneficial effects of GLP-1 breakdown products","volume":"22","author":"Guglielmi","year":"2017","journal-title":"Eat Weight Disord"},{"issue":"9","key":"2025100907021029600_bqaf130-B30","doi-asserted-by":"crossref","first-page":"890-","DOI":"10.1056\/NEJMc1615712","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"376","author":"Marso","year":"2017","journal-title":"N Engl J Med"},{"issue":"10","key":"2025100907021029600_bqaf130-B31","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/nrneph.2017.123","article-title":"GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes","volume":"13","author":"Muskiet","year":"2017","journal-title":"Nat Rev Nephrol"},{"key":"2025100907021029600_bqaf130-B32","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fendo.2019.00155","article-title":"The discovery and development of liraglutide and semaglutide","volume":"10","author":"Knudsen","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"3","key":"2025100907021029600_bqaf130-B33","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1111\/dom.13120","article-title":"Semaglutide improves postprandial glucose and lipid metabolism, and delays first-hour gastric emptying in subjects with obesity","volume":"20","author":"Hjerpsted","year":"2018","journal-title":"Diabetes Obes Metab"},{"key":"2025100907021029600_bqaf130-B34","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2020.07.008","article-title":"Semaglutide effects on cardiovascular outcomes in people with overweight or obesity (SELECT) rationale and design","volume":"229","author":"Ryan","year":"2020","journal-title":"Am Heart J"},{"issue":"1","key":"2025100907021029600_bqaf130-B35","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1038\/s41598-020-80894-x","article-title":"Dulaglutide exerts beneficial anti atherosclerotic effects in ApoE knockout mice with diabetes: the earlier, the better","volume":"11","author":"Sanada","year":"2021","journal-title":"Sci Rep"},{"issue":"24","key":"2025100907021029600_bqaf130-B36","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1056\/NEJMoa2307563","article-title":"Semaglutide and cardiovascular outcomes in obesity without diabetes","volume":"389","author":"Lincoff","year":"2023","journal-title":"N Engl J Med"},{"issue":"17","key":"2025100907021029600_bqaf130-B37","doi-asserted-by":"crossref","first-page":"6587","DOI":"10.1523\/JNEUROSCI.0529-11.2011","article-title":"The diabetes drug liraglutide prevents degenerative processes in a mouse model of Alzheimer\u2019s disease","volume":"31","author":"McClean","year":"2011","journal-title":"J Neurosci"},{"issue":"13","key":"2025100907021029600_bqaf130-B38","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMe2401743","article-title":"GLP-1, Parkinson\u2019s disease, and neuroprotection","volume":"390","author":"Standaert","year":"2024","journal-title":"N Engl J Med"},{"issue":"6","key":"2025100907021029600_bqaf130-B39","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1172\/JCI68295","article-title":"Exenatide and the treatment of patients with Parkinson\u2019s disease","volume":"123","author":"Aviles-Olmos","year":"2013","journal-title":"J Clin Invest"},{"issue":"5","key":"2025100907021029600_bqaf130-B40","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2337\/diab.26.5.480","article-title":"Synthetic gastric inhibitory polypeptide. Stimulatory effect on insulin and glucagon secretion in the rat","volume":"26","author":"Taminato","year":"1977","journal-title":"Diabetes"},{"issue":"5","key":"2025100907021029600_bqaf130-B41","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1210\/jcem-54-5-909","article-title":"The role of endogenous gastric inhibitory polypeptide in the enteroinsular axis","volume":"54","author":"Takemura","year":"1982","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"2025100907021029600_bqaf130-B42","doi-asserted-by":"crossref","first-page":"e126742","DOI":"10.1172\/jci.insight.126742","article-title":"beta cell tone is defined by proglucagon peptides through cAMP signaling","volume":"4","author":"Capozzi","year":"2019","journal-title":"JCI Insight"},{"issue":"4","key":"2025100907021029600_bqaf130-B43","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.2337\/diabetes.54.4.1056","article-title":"Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility","volume":"54","author":"Miki","year":"2005","journal-title":"Diabetes"},{"issue":"8","key":"2025100907021029600_bqaf130-B44","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.2337\/dbi24-0026","article-title":"A contemporary rationale for agonism of the GIP receptor in the treatment of obesity","volume":"74","author":"Samms","year":"2025","journal-title":"Diabetes"},{"issue":"5","key":"2025100907021029600_bqaf130-B45","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.2337\/db21-1166","article-title":"GIPR is predominantly localized to nonadipocyte cell types within white adipose tissue","volume":"71","author":"Campbell","year":"2022","journal-title":"Diabetes"},{"issue":"5","key":"2025100907021029600_bqaf130-B46","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1053\/j.gastro.2010.01.049","article-title":"Glucose-dependent insulinotropic polypeptide is expressed in pancreatic islet alpha-cells and promotes insulin secretion","volume":"138","author":"Fujita","year":"2010","journal-title":"Gastroenterology"},{"issue":"Supplement_2","key":"2025100907021029600_bqaf130-B47","doi-asserted-by":"crossref","first-page":"S251","DOI":"10.2337\/dc11-s227","article-title":"Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes","volume":"34","author":"Holst","year":"2011","journal-title":"Diabetes Care"},{"issue":"6","key":"2025100907021029600_bqaf130-B48","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.2337\/db08-0958","article-title":"Exogenous glucose-dependent insulinotropic polypeptide worsens post prandial hyperglycemia in type 2 diabetes","volume":"58","author":"Chia","year":"2009","journal-title":"Diabetes"},{"issue":"2","key":"2025100907021029600_bqaf130-B49","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/0167-0115(91)90035-F","article-title":"Influence of gastric inhibitory polypeptide (GIP) and glucose on the regulation of glucagon secretion by pancreatic alpha cells","volume":"32","author":"Opara","year":"1991","journal-title":"Regul Pept"},{"issue":"4","key":"2025100907021029600_bqaf130-B50","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.cmet.2016.08.020","article-title":"Single-cell transcriptome profiling of human pancreatic islets in health and type 2 diabetes","volume":"24","author":"Segerstolpe","year":"2016","journal-title":"Cell Metab"},{"issue":"9","key":"2025100907021029600_bqaf130-B51","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.molmet.2017.04.010","article-title":"The dynamic plasticity of insulin production in beta-cells","volume":"6","author":"Boland","year":"2017","journal-title":"Mol Metab"},{"key":"2025100907021029600_bqaf130-B52","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.molmet.2019.08.006","article-title":"Physiological roles of the GIP receptor in murine brown adipose tissue","volume":"28","author":"Beaudry","year":"2019","journal-title":"Mol Metab"},{"issue":"4","key":"2025100907021029600_bqaf130-B53","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0010-406X(65)90303-8","article-title":"Studies on the metabolism of adipose tissue. 18. In vitro effects of insulin, epinephrine and glucagon on lipolysis and glycolysis in pigeon adipose tissue","volume":"16","author":"Goodridge","year":"1965","journal-title":"Comp Biochem Physiol"},{"issue":"1 Pt 2","key":"2025100907021029600_bqaf130-B54","first-page":"R160","article-title":"Glucagon stimulation of brown adipose tissue growth and thermogenesis","volume":"252","author":"Billington","year":"1987","journal-title":"Am J Physiol"},{"issue":"5","key":"2025100907021029600_bqaf130-B55","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.2337\/db12-1116","article-title":"Fibroblast growth factor 21 mediates specific glucagon actions","volume":"62","author":"Habegger","year":"2013","journal-title":"Diabetes"},{"issue":"7","key":"2025100907021029600_bqaf130-B56","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.2337\/dci15-0033","article-title":"Clinical trials, triumphs, and tribulations of glucagon receptor antagonists","volume":"39","author":"Pearson","year":"2016","journal-title":"Diabetes Care"},{"issue":"10","key":"2025100907021029600_bqaf130-B57","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nchembio.209","article-title":"A new glucagon and GLP-1 co-agonist eliminates obesity in rodents","volume":"5","author":"Day","year":"2009","journal-title":"Nat Chem Biol"},{"key":"2025100907021029600_bqaf130-B58","doi-asserted-by":"crossref","first-page":"120188","DOI":"10.1016\/j.lfs.2021.120188","article-title":"The current significance and prospects for the use of dual receptor agonism GLP-1\/glucagon","volume":"288","author":"Spezani","year":"2022","journal-title":"Life Sci"},{"issue":"3","key":"2025100907021029600_bqaf130-B59","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1080\/14728214.2021.1947240","article-title":"Emerging glucagon-like peptide 1 receptor agonists for the treatment of obesity","volume":"26","author":"Jepsen","year":"2021","journal-title":"Expert Opin Emerg Drugs"},{"issue":"6","key":"2025100907021029600_bqaf130-B60","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"issue":"12","key":"2025100907021029600_bqaf130-B61","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/dom.12735","article-title":"Robust anti-obesity and metabolic effects of a dual GLP-1\/glucagon receptor peptide agonist in rodents and non-human primates","volume":"18","author":"Henderson","year":"2016","journal-title":"Diabetes Obes Metab"},{"issue":"Supplement_1","key":"2025100907021029600_bqaf130-B62","doi-asserted-by":"crossref","first-page":"78-OR","DOI":"10.2337\/db18-78-OR","article-title":"MEDI0382, a GLP\/glucagon receptor dual agonist, significantly reduces hepatic fat content in subjects with type 2 diabetes Mellitus","volume":"67","author":"Jain","year":"2018","journal-title":"Diabetes"},{"issue":"33","key":"2025100907021029600_bqaf130-B63","doi-asserted-by":"crossref","first-page":"e2303696120","DOI":"10.1073\/pnas.2303696120","article-title":"Structural analysis of the dual agonism at GLP-1R and GCGR","volume":"120","author":"Li","year":"2023","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2025100907021029600_bqaf130-B64","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R\/GcgR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat Metab"},{"issue":"5","key":"2025100907021029600_bqaf130-B65","doi-asserted-by":"crossref","first-page":"2443","DOI":"10.1016\/j.apsb.2021.12.016","article-title":"Design of a highly potent GLP-1R and GCGR dual-agonist for recovering hepatic fibrosis","volume":"12","author":"Song","year":"2022","journal-title":"Acta Pharm Sin B"},{"issue":"8","key":"2025100907021029600_bqaf130-B66","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1111\/dom.14412","article-title":"Pharmacokinetics, safety, tolerability, and efficacy of cotadutide, a GLP-1 and glucagon receptor dual agonist, in phase 1\/2 trials in overweight or obese participants of Asian descent with or without T2D","volume":"23","author":"Asano","year":"2021","journal-title":"Diabetes Obes Metab"},{"issue":"7","key":"2025100907021029600_bqaf130-B67","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1111\/dom.14712","article-title":"Efficacy and safety of cotadutide, a dual glucagon-like peptide-1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and chronic kidney disease","volume":"24","author":"Parker","year":"2022","journal-title":"Diabetes Obes Metab"},{"issue":"6","key":"2025100907021029600_bqaf130-B68","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1016\/j.kint.2024.08.023","article-title":"A randomized phase 2b trial examined the effects of the glucagon-like peptide-1 and glucagon receptor agonist cotadutide on kidney outcomes in patients with diabetic kidney disease","volume":"106","author":"Selvarajah","year":"2024","journal-title":"Kidney Int"},{"issue":"2","key":"2025100907021029600_bqaf130-B69","doi-asserted-by":"crossref","first-page":"e12432","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ-64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose-ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clin Obes"},{"issue":"2","key":"2025100907021029600_bqaf130-B70","doi-asserted-by":"crossref","first-page":"e12432","DOI":"10.1111\/cob.12432","article-title":"Efficacy and safety of glucagon-like peptide-1\/glucagon receptor co-agonist JNJ -64565111 in individuals with obesity without type 2 diabetes mellitus: a randomized dose-ranging study","volume":"11","author":"Alba","year":"2021","journal-title":"Clin Obes"},{"issue":"4","key":"2025100907021029600_bqaf130-B71","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1016\/j.jhep.2023.05.013","article-title":"A phase IIa active-comparator-controlled study to evaluate the efficacy and safety of efinopegdutide in patients with non-alcoholic fatty liver disease","volume":"79","author":"Romero-Gomez","year":"2023","journal-title":"J Hepatol"},{"issue":"1","key":"2025100907021029600_bqaf130-B72","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/dom.13494","article-title":"A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: results of randomized, placebo-controlled first-in-human and first-in-patient trials","volume":"21","author":"Tillner","year":"2019","journal-title":"Diabetes Obes Metab"},{"issue":"8","key":"2025100907021029600_bqaf130-B73","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1111\/dom.14394","article-title":"Improved postprandial glucose metabolism in type 2 diabetes by dual glucagon-like peptide-1\/glucagon receptor agonist SAR425899 in comparison to liraglutide","volume":"23","author":"Schiavon","year":"2021","journal-title":"Diabetes Obes Metab"},{"key":"2025100907021029600_bqaf130-B74","doi-asserted-by":"crossref","first-page":"114150","DOI":"10.1016\/j.bcp.2020.114150","article-title":"Evaluation of biased agonism mediated by dual agonists of the GLP-1 and glucagon receptors","volume":"180","author":"Darbalaei","year":"2020","journal-title":"Biochem Pharmacol"},{"key":"2025100907021029600_bqaf130-B75","doi-asserted-by":"crossref","first-page":"110779","DOI":"10.1016\/j.diabres.2023.110779","article-title":"Perspectives in weight control in diabetes\u2014survodutide","volume":"207","author":"Klein","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"issue":"4","key":"2025100907021029600_bqaf130-B76","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.2337\/db12-0797","article-title":"Coadministration of glucagon-like peptide-1 during glucagon infusion in humans results in increased energy expenditure and amelioration of hyperglycemia","volume":"62","author":"Tan","year":"2013","journal-title":"Diabetes"},{"issue":"Supplement_1","key":"2025100907021029600_bqaf130-B77","doi-asserted-by":"crossref","DOI":"10.2337\/db23-51-OR","article-title":"51-OR: a phase 2, randomized, double-blind, placebo-controlled, dose-finding study of BI 456906 in people with overweight\/obesity","volume":"72","author":"Le Roux","year":"2023","journal-title":"Diabetes"},{"issue":"Supplement_1","key":"2025100907021029600_bqaf130-B78","doi-asserted-by":"crossref","DOI":"10.2337\/db22-723-P","article-title":"723-P: the dual glucagon and glucagon-like peptide-1 receptor (GCGR\/GLP-1R) agonist BI 4569Reduces body weight in diet-induced obese mice based on food intake reduction and an increase in energy expenditure","volume":"71","author":"Zimmermann","year":"2022","journal-title":"Diabetes"},{"issue":"1","key":"2025100907021029600_bqaf130-B79","doi-asserted-by":"crossref","first-page":"160","DOI":"10.2337\/dc23-1287","article-title":"Efficacy and safety of mazdutide in Chinese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled phase 2 trial","volume":"47","author":"Zhang","year":"2024","journal-title":"Diabetes Care"},{"issue":"Supplement_1","key":"2025100907021029600_bqaf130-B80","doi-asserted-by":"crossref","DOI":"10.2337\/db22-334-OR","article-title":"334-OR: pemvidutide (ALT-801), a balanced (1: 1) GLP-1\/glucagon dual receptor agonist, induces rapid and marked weight loss without the need for dose titration in people with overweight\/obesity","volume":"71","author":"Klein","year":"2022","journal-title":"Diabetes"},{"issue":"10","key":"2025100907021029600_bqaf130-B81","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1111\/dom.13025","article-title":"Pharmacodynamics, pharmacokinetics, safety and tolerability of the novel dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 agonist RG7697 after single subcutaneous administration in healthy subjects","volume":"19","author":"Portron","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"10","key":"2025100907021029600_bqaf130-B82","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/dom.13024","article-title":"Pharmacodynamics, pharmacokinetics and safety of multiple ascending doses of the novel dual glucose-dependent insulinotropic polypeptide\/glucagon-like peptide-1 agonist RG7697 in people with type 2 diabetes mellitus","volume":"19","author":"Schmitt","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"10401","key":"2025100907021029600_bqaf130-B83","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0140-6736(23)01053-X","article-title":"Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA","volume":"402","author":"Rosenstock","year":"2023","journal-title":"Lancet"},{"issue":"Supplement_1","key":"2025100907021029600_bqaf130-B84","doi-asserted-by":"crossref","first-page":"1830-P","DOI":"10.2337\/db20-1830-P","article-title":"1830-P: therapeutic effect of a novel long-acting GLP-1\/GIP\/glucagon triple agonist (HM15211) in CDHFD-induced NASH and fibrosis mice","volume":"69","author":"Choi","year":"2020","journal-title":"Diabetes"},{"issue":"Supplement 1","key":"2025100907021029600_bqaf130-B85","doi-asserted-by":"crossref","first-page":"655-P","DOI":"10.2337\/db21-655-P","article-title":"655-P: multitarget engagement effect of a novel long-acting glucagon\/GIP\/GLP-1 triple agonist (HM15211) in animal model of NASH","volume":"70","author":"Kim","year":"2021","journal-title":"Diabetes"},{"issue":"Supplement_1","key":"2025100907021029600_bqaf130-B86","doi-asserted-by":"crossref","first-page":"1810-P","DOI":"10.2337\/db19-1810-P","article-title":"1810-P: effect of HM15211, a novel long-acting GLP-1\/GIP\/glucagon triple agonist in the neurodegenerative disease models","volume":"68","author":"Wonki","year":"2019","journal-title":"Diabetes"},{"issue":"Supplement_1","key":"2025100907021029600_bqaf130-B87","doi-asserted-by":"crossref","first-page":"996-P","DOI":"10.2337\/db19-996-P","article-title":"996-P: therapeutic effect of a novel long-acting GLP-1\/GIP\/glucagon triple agonist (HM15211) in a dyslipidemia animal model","volume":"68","author":"Choi","year":"2019","journal-title":"Diabetes"},{"issue":"7795","key":"2025100907021029600_bqaf130-B88","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41586-019-1911-y","article-title":"GDF15 mediates the effects of metformin on body weight and energy balance","volume":"578","author":"Coll","year":"2020","journal-title":"Nature"},{"issue":"4","key":"2025100907021029600_bqaf130-B89","doi-asserted-by":"crossref","first-page":"bnaa007","DOI":"10.1210\/endrev\/bnaa007","article-title":"GDF15: a hormone conveying somatic distress to the brain","volume":"41","author":"Lockhart","year":"2020","journal-title":"Endocr Rev"},{"issue":"10","key":"2025100907021029600_bqaf130-B90","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/s41574-021-00529-7","article-title":"GDF15: emerging biology and therapeutic applications for obesity and cardiometabolic disease","volume":"17","author":"Wang","year":"2021","journal-title":"Nat Rev Endocrinol"},{"issue":"2","key":"2025100907021029600_bqaf130-B91","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1373\/clinchem.2010.153726","article-title":"The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients","volume":"57","author":"Vila","year":"2011","journal-title":"Clin Chem"},{"issue":"4","key":"2025100907021029600_bqaf130-B92","doi-asserted-by":"crossref","first-page":"E615","DOI":"10.1152\/ajpendo.00010.2019","article-title":"Effect of bariatric surgery on plasma GDF15 in humans","volume":"316","author":"Kleinert","year":"2019","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"19","key":"2025100907021029600_bqaf130-B93","doi-asserted-by":"crossref","first-page":"2346","DOI":"10.1093\/eurheartj\/ehp261","article-title":"Growth-differentiation factor-15 is an independent marker of cardiovascular dysfunction and disease in the elderly: results from the prospective investigation of the vasculature in Uppsala seniors (PIVUS) study","volume":"30","author":"Lind","year":"2009","journal-title":"Eur Heart J"},{"issue":"1","key":"2025100907021029600_bqaf130-B94","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/2047-783X-18-19","article-title":"GDF-15 protects from macrophage accumulation in a mousemodel of advanced atherosclerosis","volume":"18","author":"Preusch","year":"2013","journal-title":"Eur J Med Res"},{"issue":"5","key":"2025100907021029600_bqaf130-B95","doi-asserted-by":"crossref","first-page":"101369","DOI":"10.1016\/j.diabet.2022.101369","article-title":"Liraglutide-induced effects on energy intake and glycemic profile are independent of total and intact GDF-15 levels in subjects with obesity and diabetes","volume":"48","author":"Valenzuela-Vallejo","year":"2022","journal-title":"Diabetes Metab"},{"issue":"2","key":"2025100907021029600_bqaf130-B96","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.cmet.2023.01.001","article-title":"Activity-balanced GLP-1\/GDF15 dual agonist reduces body weight and metabolic disorder in mice and non-human primates","volume":"35","author":"Zhang","year":"2023","journal-title":"Cell Metab"},{"issue":"2","key":"2025100907021029600_bqaf130-B97","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2337\/db21-0659","article-title":"Regulatory T cells control effector T cell inflammation in human prediabetes","volume":"71","author":"Liu","year":"2022","journal-title":"Diabetes"},{"issue":"9","key":"2025100907021029600_bqaf130-B98","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s11892-017-0900-5","article-title":"T cell populations and functions are altered in human obesity and type 2 diabetes","volume":"17","author":"Touch","year":"2017","journal-title":"Curr Diab Rep"},{"issue":"6","key":"2025100907021029600_bqaf130-B99","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.2337\/db13-1511","article-title":"T cell-derived IL-22 amplifies IL-1beta-driven inflammation in human adipose tissue: relevance to obesity and type 2 diabetes","volume":"63","author":"Dalmas","year":"2014","journal-title":"Diabetes"},{"issue":"10258","key":"2025100907021029600_bqaf130-B100","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0140-6736(20)30752-2","article-title":"Global burden of 87 risk factors in 204 countries and territories, 1990\u20132019: a systematic analysis for the global burden of disease study 2019","volume":"396","author":"GBD 2019 Risk Factors Collaborators","year":"2020","journal-title":"Lancet"},{"key":"2025100907021029600_bqaf130-B101","doi-asserted-by":"crossref","first-page":"3094642","DOI":"10.1155\/2016\/3094642","article-title":"Anti-inflammatory effects of GLP-1-based therapies beyond glucose control","volume":"2016","author":"Lee","year":"2016","journal-title":"Mediators Inflamm"},{"key":"2025100907021029600_bqaf130-B102","doi-asserted-by":"crossref","first-page":"171200","DOI":"10.1016\/j.peptides.2024.171200","article-title":"Immunomodulation and inflammation: role of GLP-1R and GIPR expressing cells within the gut","volume":"176","author":"Morrow","year":"2024","journal-title":"Peptides"},{"key":"2025100907021029600_bqaf130-B103","doi-asserted-by":"crossref","first-page":"20420188231222367","DOI":"10.1177\/20420188231222367","article-title":"Anti-inflammatory role of glucagon-like peptide 1 receptor agonists and its clinical implications","volume":"15","author":"Alharbi","year":"2024","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"11","key":"2025100907021029600_bqaf130-B104","doi-asserted-by":"crossref","first-page":"4040","DOI":"10.1016\/j.apsb.2022.06.003","article-title":"The anti-inflammatory feature of glucagon-like peptide-1 and its based diabetes drugs-therapeutic potential exploration in lung injury","volume":"12","author":"Pang","year":"2022","journal-title":"Acta Pharm Sin B"},{"issue":"5","key":"2025100907021029600_bqaf130-B105","doi-asserted-by":"crossref","first-page":"187","DOI":"10.3109\/08977194.2011.607137","article-title":"The TGF-beta superfamily cytokine, MIC-1\/GDF15: a pleotrophic cytokine with roles in inflammation, cancer and metabolism","volume":"29","author":"Breit","year":"2011","journal-title":"Growth Factors"},{"key":"2025100907021029600_bqaf130-B106","doi-asserted-by":"crossref","first-page":"710977","DOI":"10.3389\/fimmu.2021.710977","article-title":"The clinical value of GDF15 and its prospective mechanism in sepsis","volume":"12","author":"Li","year":"2021","journal-title":"Front Immunol"},{"issue":"5","key":"2025100907021029600_bqaf130-B107","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/nm.2354","article-title":"GDF-15 is an inhibitor of leukocyte integrin activation required for survival after myocardial infarction in mice","volume":"17","author":"Kempf","year":"2011","journal-title":"Nat Med"},{"issue":"2","key":"2025100907021029600_bqaf130-B108","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1007\/s00441-004-0986-3","article-title":"Involvement of growth differentiation factor-15\/macrophage inhibitory cytokine-1 (GDF-15\/MIC-1) in oxLDL-induced apoptosis of human macrophages in vitro and in arteriosclerotic lesions","volume":"318","author":"Schlittenhardt","year":"2004","journal-title":"Cell Tissue Res"},{"issue":"12","key":"2025100907021029600_bqaf130-B109","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.humimm.2021.06.007","article-title":"Roles and regulation of growth differentiation factor-15 in the immune and tumor microenvironment","volume":"82","author":"Lodi","year":"2021","journal-title":"Hum Immunol"},{"issue":"1","key":"2025100907021029600_bqaf130-B110","doi-asserted-by":"crossref","first-page":"4253","DOI":"10.1038\/s41467-023-39817-3","article-title":"Tumor-derived GDF-15 blocks LFA-1 dependent T cell recruitment and suppresses responses to anti-PD-1 treatment","volume":"14","author":"Haake","year":"2023","journal-title":"Nat Commun"},{"issue":"5","key":"2025100907021029600_bqaf130-B111","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.jcmgh.2023.07.009","article-title":"GDF15 ameliorates liver fibrosis by metabolic reprogramming of macrophages to acquire anti-inflammatory properties","volume":"16","author":"Li","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"2025100907021029600_bqaf130-B112","doi-asserted-by":"crossref","first-page":"170225","DOI":"10.1016\/j.peptides.2019.170225","article-title":"Selection and progression of unimolecular agonists at the GIP, GLP-1, and glucagon receptors as drug candidates","volume":"125","author":"Knerr","year":"2020","journal-title":"Peptides"},{"issue":"1","key":"2025100907021029600_bqaf130-B113","doi-asserted-by":"crossref","first-page":"12","DOI":"10.3803\/EnM.2024.1942","article-title":"The road towards triple agonists: glucagon-like peptide 1, glucose-dependent insulinotropic polypeptide and glucagon receptor\u2014an update","volume":"39","author":"Jakubowska","year":"2024","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"8","key":"2025100907021029600_bqaf130-B114","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s00125-015-3618-4","article-title":"GIP increases adipose tissue expression and blood levels of MCP-1 in humans and links high energy diets to inflammation: a randomised trial","volume":"58","author":"Gogebakan","year":"2015","journal-title":"Diabetologia"},{"issue":"1","key":"2025100907021029600_bqaf130-B115","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s13181-022-00919-x","article-title":"Cardiovascular and adverse effects of glucagon for the management of suspected Beta blocker toxicity: a case series","volume":"19","author":"Senart","year":"2023","journal-title":"J Med Toxicol"},{"issue":"2","key":"2025100907021029600_bqaf130-B116","doi-asserted-by":"crossref","first-page":"264","DOI":"10.2337\/dc15-1498","article-title":"Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: a randomized crossover noninferiority study","volume":"39","author":"Rickels","year":"2016","journal-title":"Diabetes Care"},{"issue":"3","key":"2025100907021029600_bqaf130-B117","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1148\/radiology.202.3.9051052","article-title":"Severe allergic reaction to intravenous injection of glucagon","volume":"202","author":"Herskovitz","year":"1997","journal-title":"Radiology"},{"key":"2025100907021029600_bqaf130-B118","author":"Morris"},{"issue":"1","key":"2025100907021029600_bqaf130-B119","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1001\/archinte.1989.00390010176027","article-title":"Improved safety of glucagon testing for pheochromocytoma by prior alpha-receptor blockade. A controlled trial in a patient with a mixed ganglioneuroma\/pheochromocytoma","volume":"149","author":"Elliott","year":"1989","journal-title":"Arch Intern Med"},{"issue":"1","key":"2025100907021029600_bqaf130-B120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3803\/EnM.2022.1642","article-title":"Glucagon-like peptide 1 therapy: from discovery to type 2 diabetes and beyond","volume":"38","author":"Viljoen","year":"2023","journal-title":"Endocrinol Metab (Seoul)"},{"key":"2025100907021029600_bqaf130-B121","doi-asserted-by":"crossref","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13:","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"2025100907021029600_bqaf130-B122","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1177\/11795514211051697","article-title":"Role of glucagon-like peptide-1 (GLP-1) receptor agonists in hypoglycemia","volume":"14","author":"Ja\u2019arah","year":"2021","journal-title":"Clin Med Insights Endocrinol Diabetes"},{"issue":"3","key":"2025100907021029600_bqaf130-B123","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1464-5491.2009.02666.x","article-title":"Liraglutide, a once-daily human GLP-1 analogue, added to a sulfonylurea over 26 weeks produces greater improvements in glycemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU)","volume":"26","author":"Marre","year":"2009","journal-title":"Diabet Med"},{"issue":"10","key":"2025100907021029600_bqaf130-B124","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1007\/s00125-009-1472-y","article-title":"Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial","volume":"52","author":"Russell-Jones","year":"2009","journal-title":"Diabetologia"},{"issue":"6","key":"2025100907021029600_bqaf130-B125","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1042\/cs0950719","article-title":"Subcutaneous glucagon-like peptide-I (7\u201336) amide is insulinotropic and can cause hypoglycaemia in fasted healthy subjects","volume":"95","author":"Edwards","year":"1998","journal-title":"Clinical Science (London, England: 1979)"},{"issue":"18","key":"2025100907021029600_bqaf130-B126","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1001\/jama.2023.19574","article-title":"Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss","volume":"330","author":"Sodhi","year":"2023","journal-title":"JAMA"},{"issue":"7","key":"2025100907021029600_bqaf130-B127","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1001\/jamainternmed.2013.2720","article-title":"Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes Mellitus: a population-based matched case-control study","volume":"173","author":"Singh","year":"2013","journal-title":"JAMA Intern Med"},{"issue":"8","key":"2025100907021029600_bqaf130-B128","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1097\/MPA.0b013e31824e67a3","article-title":"Exenatide-induced chronic damage of pancreatic tissue in rats","volume":"41","author":"Yu","year":"2012","journal-title":"Pancreas"},{"issue":"3-4","key":"2025100907021029600_bqaf130-B129","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1900\/RDS.2014.11.202","article-title":"Adverse effects of GLP-1 receptor agonists","volume":"11","author":"Filippatos","year":"2014","journal-title":"Rev Diabet Stud"},{"issue":"8","key":"2025100907021029600_bqaf130-B130","doi-asserted-by":"crossref","first-page":"e104873","DOI":"10.1371\/journal.pone.0104873","article-title":"Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia","volume":"9","author":"Mondragon","year":"2014","journal-title":"PLoS One"},{"issue":"4","key":"2025100907021029600_bqaf130-B131","doi-asserted-by":"crossref","first-page":"472","DOI":"10.4158\/EP11290.OR","article-title":"Elevated amylase and lipase levels in patients using glucagonlike peptide-1 receptor agonists or dipeptidyl-peptidase-4 inhibitors in the outpatient setting","volume":"18","author":"Lando","year":"2012","journal-title":"Endocr Pract"},{"key":"2025100907021029600_bqaf130-B132","doi-asserted-by":"crossref","first-page":"155182","DOI":"10.1016\/j.cyto.2020.155182","article-title":"Glucagon-like peptide-1 is associated with poor clinical outcome, lipopolysaccharide translocation and inflammation in patients undergoing cardiac surgery with cardiopulmonary bypass","volume":"133","author":"Nguyen","year":"2020","journal-title":"Cytokine"},{"issue":"1","key":"2025100907021029600_bqaf130-B133","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1186\/s12933-014-0142-7","article-title":"Cardiovascular effects of glucagon-like peptide 1 (GLP-1) receptor agonists","volume":"13","author":"Saraiva","year":"2014","journal-title":"Cardiovasc Diabetol"},{"issue":"1","key":"2025100907021029600_bqaf130-B134","doi-asserted-by":"crossref","first-page":"e001986","DOI":"10.1136\/bmjopen-2012-001986","article-title":"Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis","volume":"3","author":"Robinson","year":"2013","journal-title":"BMJ Open"},{"issue":"8","key":"2025100907021029600_bqaf130-B135","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.2337\/dc13-2760","article-title":"Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-1)","volume":"37","author":"Wysham","year":"2014","journal-title":"Diabetes Care"},{"issue":"2","key":"2025100907021029600_bqaf130-B136","doi-asserted-by":"crossref","first-page":"F231","DOI":"10.1152\/ajprenal.00432.2018","article-title":"Renal tubular effects of prolonged therapy with the GLP-1 receptor agonist lixisenatide in patients with type 2 diabetes mellitus","volume":"316","author":"Tonneijck","year":"2019","journal-title":"Am J Physiol Renal Physiol"},{"issue":"6","key":"2025100907021029600_bqaf130-B137","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1002\/pdi.1493","article-title":"Exenatide associated renal failure","volume":"27","author":"Bhatti","year":"2010","journal-title":"Pract Diabetes Int"},{"issue":"5","key":"2025100907021029600_bqaf130-B138","doi-asserted-by":"crossref","first-page":"190","DOI":"10.4239\/wjd.v4.i5.190","article-title":"Effects of glucagon-like peptide-1 receptor agonists on renal function","volume":"4","author":"Filippatos","year":"2013","journal-title":"World J Diabetes"},{"issue":"4","key":"2025100907021029600_bqaf130-B139","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1111\/j.1365-2125.2008.03221.x","article-title":"Exenatide may aggravate moderate diabetic renal impairment: a case report","volume":"66","author":"Johansen","year":"2008","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2025100907021029600_bqaf130-B140","doi-asserted-by":"crossref","first-page":"e22","DOI":"10.2337\/dc08-1309","article-title":"Exenatide-associated ischemic renal failure","volume":"32","author":"Weise","year":"2009","journal-title":"Diabetes Care"},{"issue":"2","key":"2025100907021029600_bqaf130-B141","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1053\/j.ajkd.2013.10.057","article-title":"Acute interstitial nephritis after treatment with liraglutide","volume":"63","author":"Gariani","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"2025100907021029600_bqaf130-B142","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1111\/j.1464-5491.2012.03738.x","article-title":"Acute interstitial nephritis following treatment with exenatide","volume":"30","author":"Nandakoban","year":"2013","journal-title":"Diabet Med"},{"key":"2025100907021029600_bqaf130-B143","first-page":"676","article-title":"Lixisenatide (adlyxin): a once-daily incretin mimetic injection for type-2 diabetes","volume":"42","author":"Leon","year":"2017","journal-title":"P T"},{"key":"2025100907021029600_bqaf130-B144","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.diabres.2017.02.017","article-title":"Albiglutide for the treatment of type 2 diabetes mellitus: an integrated safety analysis of the HARMONY phase 3 trials","volume":"126","author":"Ahr\u00e9n","year":"2017","journal-title":"Diabetes Res Clin Pract"},{"key":"2025100907021029600_bqaf130-B145","first-page":"241","article-title":"Safety and tolerability of exenatide once weekly in patients with type 2 diabetes: an integrated analysis of 4,328 patients","volume":"8","author":"Macconell","year":"2015","journal-title":"Diabetes Metab Syndr Obes"},{"issue":"5","key":"2025100907021029600_bqaf130-B146","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/j.1463-1326.2011.01357.x","article-title":"An overview of once-weekly GLP-1 receptor agonists- available efficacy and safety data and perspectives for the future","volume":"13","author":"Madsbad","year":"2011","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"2025100907021029600_bqaf130-B147","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1210\/clinem\/dgad532","article-title":"Tirzepatide immunogenicity on pharmacokinetics, efficacy, and safety: analysis of data from phase 3 studies","volume":"109","author":"Mullins","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025100907021029600_bqaf130-B148","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1111\/j.1463-1326.2012.01561.x","article-title":"Clinical relevance of anti-exenatide antibodies: safety, efficacy and cross-reactivity with long-term treatment","volume":"14","author":"Fineman","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"2025100907021029600_bqaf130-B149","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12020-014-0361-4","article-title":"Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists\u2019 treatment: a meta-analysis of randomized controlled trials","volume":"48","author":"Su","year":"2015","journal-title":"Endocrine"},{"issue":"12","key":"2025100907021029600_bqaf130-B150","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/1753-0407.13334","article-title":"Metformin and growth differentiation factor 15 (GDF15) in type 2 diabetes mellitus: a hidden treasure","volume":"14","author":"Al-Kuraishy","year":"2022","journal-title":"J Diabetes"},{"issue":"3","key":"2025100907021029600_bqaf130-B151","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/iep.12398","article-title":"Identification of growth differentiation factor 15 as a pro-fibrotic factor in mouse liver fibrosis progression","volume":"102","author":"Qi","year":"2021","journal-title":"Int J Exp Pathol"},{"issue":"1","key":"2025100907021029600_bqaf130-B152","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.jhep.2021.08.009","article-title":"Mitochondrial dysfunction governs immunometabolism in leukocytes of patients with acute-on-chronic liver failure","volume":"76","author":"Zhang","year":"2022","journal-title":"J Hepatol"},{"issue":"9","key":"2025100907021029600_bqaf130-B153","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1111\/jcmm.17725","article-title":"Overview of growth differentiation factor 15 in metabolic syndrome","volume":"27","author":"Asrih","year":"2023","journal-title":"J Cell Mol Med"},{"issue":"6","key":"2025100907021029600_bqaf130-B154","doi-asserted-by":"crossref","first-page":"e002550","DOI":"10.1161\/JAHA.112.002550","article-title":"Growth differentiation factor-15 deficiency inhibits atherosclerosis progression by regulating interleukin-6\u2013dependent inflammatory response to vascular injury","volume":"1","author":"Bonaterra","year":"2012","journal-title":"J Am Heart Assoc"},{"key":"2025100907021029600_bqaf130-B155","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2018.12.009","article-title":"Growth differentiation factor-15 regulates oxLDL-induced lipid homeostasis and autophagy in human macrophages","volume":"281","author":"Ackermann","year":"2019","journal-title":"Atherosclerosis"}],"container-title":["Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/endo\/advance-article-pdf\/doi\/10.1210\/endocr\/bqaf130\/64067946\/bqaf130.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/166\/11\/bqaf130\/64067946\/bqaf130.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/endo\/article-pdf\/166\/11\/bqaf130\/64067946\/bqaf130.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T11:02:34Z","timestamp":1760007754000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/endo\/article\/doi\/10.1210\/endocr\/bqaf130\/8236487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,16]]},"references-count":155,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10,9]]}},"URL":"https:\/\/doi.org\/10.1210\/endocr\/bqaf130","relation":{},"ISSN":["1945-7170"],"issn-type":[{"value":"1945-7170","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,8,16]]},"article-number":"bqaf130"}}